LT3532067T - Liposominė vaisto forma, skirta naudoti gydant vėžį - Google Patents
Liposominė vaisto forma, skirta naudoti gydant vėžįInfo
- Publication number
- LT3532067T LT3532067T LTEPPCT/EP2017/077538T LT17077538T LT3532067T LT 3532067 T LT3532067 T LT 3532067T LT 17077538 T LT17077538 T LT 17077538T LT 3532067 T LT3532067 T LT 3532067T
- Authority
- LT
- Lithuania
- Prior art keywords
- cancer
- treatment
- liposomal formulation
- liposomal
- formulation
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306415 | 2016-10-28 | ||
| PCT/EP2017/077538 WO2018078064A1 (en) | 2016-10-28 | 2017-10-27 | Liposomal formulation for use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3532067T true LT3532067T (lt) | 2022-08-25 |
Family
ID=57288337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/EP2017/077538T LT3532067T (lt) | 2016-10-28 | 2017-10-27 | Liposominė vaisto forma, skirta naudoti gydant vėžį |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US10722466B2 (lt) |
| EP (1) | EP3532067B1 (lt) |
| JP (1) | JP7041676B2 (lt) |
| KR (1) | KR102653436B1 (lt) |
| CN (1) | CN109922808B (lt) |
| AR (1) | AR109981A1 (lt) |
| AU (1) | AU2017350499B2 (lt) |
| BR (1) | BR112019008263A2 (lt) |
| CA (1) | CA3041592C (lt) |
| CO (1) | CO2019004190A2 (lt) |
| CU (1) | CU20190046A7 (lt) |
| DK (1) | DK3532067T3 (lt) |
| EA (1) | EA201991025A1 (lt) |
| ES (1) | ES2923929T3 (lt) |
| GE (1) | GEP20217244B (lt) |
| HR (1) | HRP20220952T1 (lt) |
| HU (1) | HUE059448T2 (lt) |
| IL (1) | IL266198B2 (lt) |
| LT (1) | LT3532067T (lt) |
| MA (1) | MA46608B1 (lt) |
| MD (1) | MD3532067T2 (lt) |
| MX (1) | MX2019004941A (lt) |
| MY (1) | MY194730A (lt) |
| PH (1) | PH12019500804A1 (lt) |
| PL (1) | PL3532067T3 (lt) |
| PT (1) | PT3532067T (lt) |
| RS (1) | RS63400B1 (lt) |
| RU (1) | RU2756755C2 (lt) |
| SG (1) | SG11201903326RA (lt) |
| SI (1) | SI3532067T1 (lt) |
| TN (1) | TN2019000117A1 (lt) |
| TW (1) | TWI749091B (lt) |
| UA (1) | UA126910C2 (lt) |
| UY (1) | UY37459A (lt) |
| WO (1) | WO2018078064A1 (lt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200041942A (ko) | 2017-08-15 | 2020-04-22 | 애브비 인코포레이티드 | 거대환식 mcl-1 저해제 및 이의 용도 |
| CN110964034B (zh) * | 2018-09-29 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用 |
| AR116635A1 (es) * | 2018-10-15 | 2021-05-26 | Servier Lab | Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen |
| TW202038960A (zh) | 2018-11-14 | 2020-11-01 | 法商施維雅藥廠 | Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物 |
| AR119156A1 (es) | 2019-06-17 | 2021-11-24 | Servier Lab | Combinación de un inhibidor de mcl-1 y un tratamiento estándar de atención médica para cáncer de mama, usos y composiciones farmacéuticas de la misma |
| WO2022090443A1 (en) | 2020-10-30 | 2022-05-05 | Les Laboratoires Servier | Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor |
| WO2022212863A1 (en) | 2021-04-01 | 2022-10-06 | Vestaron Corporation | Liposome formulations for pesticide delivery and methods for producing and using the same |
| AU2022291381A1 (en) | 2021-06-11 | 2023-11-30 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| US11931424B2 (en) | 2021-06-11 | 2024-03-19 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-body drug conjugates |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS607932A (ja) * | 1983-06-29 | 1985-01-16 | Dai Ichi Seiyaku Co Ltd | リポソーム懸濁液およびその製法 |
| GB8613811D0 (en) | 1986-06-06 | 1986-07-09 | Phares Pharm Res Nv | Composition & method |
| US5580899A (en) * | 1995-01-09 | 1996-12-03 | The Liposome Company, Inc. | Hydrophobic taxane derivatives |
| GB9601120D0 (en) | 1996-01-19 | 1996-03-20 | Sandoz Ltd | Organic compounds |
| EP1013268A1 (en) * | 1998-06-30 | 2000-06-28 | Rohto Pharmaceutical Co., Ltd. | Compositions containing liposomes and/or emulsions and process for the preparation thereof |
| CZ2002850A3 (cs) * | 1999-09-09 | 2003-04-16 | The Regents Of The University Of California | Kationtový liposom a použití kationtového liposomového prostředku |
| KR20010100194A (ko) * | 2000-03-13 | 2001-11-14 | 박호군 | 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법 |
| JP2002080400A (ja) * | 2000-06-23 | 2002-03-19 | Takeda Chem Ind Ltd | リン脂質含有薬物の製造法 |
| CN1116875C (zh) * | 2000-10-19 | 2003-08-06 | 南京振中生物工程有限公司 | 紫杉醇脂质组合物及其制备方法 |
| JP2004524368A (ja) | 2001-03-27 | 2004-08-12 | フェアーズ ファーマシューティカル リサーチ エヌ．ヴェー． | 低い水溶性を有する生物学的に活性な化合物を可溶化するための方法および組成物 |
| US7666876B2 (en) * | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
| JP4711947B2 (ja) * | 2003-02-03 | 2011-06-29 | ネオファーム、インコーポレイティッド | 安定な濾過滅菌性リポソームに被包化されたタキサン及び他の抗腫瘍剤 |
| JP2005075783A (ja) * | 2003-09-01 | 2005-03-24 | Otsuka Pharmaceut Factory Inc | 難溶性化合物の可溶化または分散化用組成物 |
| JP2005225818A (ja) * | 2004-02-13 | 2005-08-25 | Otsuka Pharmaceut Factory Inc | パクリタキセル又はドセタキセルの医薬組成物 |
| CA2681302C (en) | 2007-03-19 | 2013-07-23 | Dhiraj Khattar | Proliposomal and liposomal compositions of poorly water-soluble compounds |
| EP2344198B1 (en) | 2008-09-27 | 2020-11-04 | Jina Pharmaceuticals Inc. | Lipid based pharmaceutical preparations for topical application |
| RU2476216C1 (ru) * | 2009-03-30 | 2013-02-27 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Липосомальная композиция |
| DK2508170T3 (en) * | 2009-12-03 | 2015-09-21 | Jiangsu Hengrui Medicine Co | LIPOSOM OF IRINOTECAN OR ITS HYDROCHLORIDE AND ITS PROCEDURE |
| JP2012051823A (ja) * | 2010-08-31 | 2012-03-15 | Fujifilm Corp | 難容性薬物含有水中油型乳化組成物及びその製造方法 |
| CN101926757B (zh) * | 2010-09-01 | 2013-01-02 | 北京大学 | 一种难溶性药物的液体组合物及其制备方法 |
| CN103237542A (zh) * | 2010-12-08 | 2013-08-07 | 霍夫曼-拉罗奇有限公司 | 达塞曲匹的脂质体制剂 |
| EP2680820B1 (en) * | 2011-03-01 | 2022-11-02 | 2-BBB Medicines B.V. | Advanced active liposomal loading of poorly water-soluble substances |
| CN103622911B (zh) | 2013-11-19 | 2015-12-30 | 常州金远药业制造有限公司 | 一种难溶性药物脂质体制备方法 |
| FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2017
- 2017-10-27 ES ES17787939T patent/ES2923929T3/es active Active
- 2017-10-27 HU HUE17787939A patent/HUE059448T2/hu unknown
- 2017-10-27 UY UY0001037459A patent/UY37459A/es unknown
- 2017-10-27 RU RU2019115688A patent/RU2756755C2/ru active
- 2017-10-27 MY MYPI2019002297A patent/MY194730A/en unknown
- 2017-10-27 KR KR1020197015033A patent/KR102653436B1/ko active IP Right Grant
- 2017-10-27 TW TW106137030A patent/TWI749091B/zh active
- 2017-10-27 AU AU2017350499A patent/AU2017350499B2/en active Active
- 2017-10-27 DK DK17787939.2T patent/DK3532067T3/da active
- 2017-10-27 MX MX2019004941A patent/MX2019004941A/es unknown
- 2017-10-27 RS RS20220677A patent/RS63400B1/sr unknown
- 2017-10-27 US US16/344,431 patent/US10722466B2/en active Active
- 2017-10-27 TN TNP/2019/000117A patent/TN2019000117A1/en unknown
- 2017-10-27 CA CA3041592A patent/CA3041592C/en active Active
- 2017-10-27 WO PCT/EP2017/077538 patent/WO2018078064A1/en active Application Filing
- 2017-10-27 GE GEAP201715047A patent/GEP20217244B/en unknown
- 2017-10-27 JP JP2019522453A patent/JP7041676B2/ja active Active
- 2017-10-27 IL IL266198A patent/IL266198B2/en unknown
- 2017-10-27 AR ARP170102984A patent/AR109981A1/es unknown
- 2017-10-27 CN CN201780067045.2A patent/CN109922808B/zh active Active
- 2017-10-27 SI SI201731200T patent/SI3532067T1/sl unknown
- 2017-10-27 PL PL17787939.2T patent/PL3532067T3/pl unknown
- 2017-10-27 UA UAA201905614A patent/UA126910C2/uk unknown
- 2017-10-27 BR BR112019008263A patent/BR112019008263A2/pt unknown
- 2017-10-27 EA EA201991025A patent/EA201991025A1/ru unknown
- 2017-10-27 SG SG11201903326RA patent/SG11201903326RA/en unknown
- 2017-10-27 HR HRP20220952TT patent/HRP20220952T1/hr unknown
- 2017-10-27 EP EP17787939.2A patent/EP3532067B1/en active Active
- 2017-10-27 CU CU2019000046A patent/CU20190046A7/es unknown
- 2017-10-27 PT PT177879392T patent/PT3532067T/pt unknown
- 2017-10-27 MD MDE20190973T patent/MD3532067T2/ro unknown
- 2017-10-27 LT LTEPPCT/EP2017/077538T patent/LT3532067T/lt unknown
- 2017-10-27 MA MA46608A patent/MA46608B1/fr unknown
-
2019
- 2019-04-12 PH PH12019500804A patent/PH12019500804A1/en unknown
- 2019-04-26 CO CONC2019/0004190A patent/CO2019004190A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266198A (en) | Liposomal formulation for use in cancer treatment | |
| HK1256283A1 (zh) | 治療癌症有用的二氫咪唑並吡嗪酮衍生物 | |
| ZA201607415B (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| ZA201807810B (en) | Adenosine derivatives for use in the treatment of cancer | |
| LT3473263T (lt) | Kombinuoti preparatai, skirti vėžio gydymui | |
| IL276733A (en) | Use of Aribolin in cancer treatment | |
| IL248767B (en) | Trimethoxyphenyl-benzaimidazole compounds for cancer treatment | |
| IL251903B (en) | Epilimod for use in the treatment of colon cancer | |
| EP3337784A4 (en) | USE OF UREIDOMUSTIN (BO-1055) IN THE TREATMENT OF CANCER | |
| EP3440052C0 (en) | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | |
| IL253933A0 (en) | History of pyrimidine use in the treatment of cancer | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| EP3471720A4 (en) | FORMULAS FOR USE IN THE TREATMENT OF UREMAN PRURITUS | |
| IL249860A0 (en) | Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer | |
| GB201514018D0 (en) | Novel tricyclic compounds and their use in the treatment of cancer | |
| ZA201902951B (en) | Nutritional composition for use in therapy of cancer patients | |
| IL273054A (en) | ABX196 for use in the treatment of bladder cancer | |
| EP3434271A4 (en) | USE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF A GAUZE SYTHEM IN POIKILODERMIA |